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Abstract
How to manage patients with prostate cancer (PCa) with bio-
chemical recurrence (BCR) following primary curative treat-
ment is a controversial issue. Importantly, this prostate-spe-
cific antigen (PSA)-only recurrence is a surrogate neither of 
PCa-specific survival nor of overall survival. Physicians are 
therefore challenged with preventing or delaying the onset 
of clinical progression in those deemed at risk, while avoid-
ing over-treating patients whose disease may never prog-
ress beyond PSA-only recurrence. Adjuvant therapy for radi-
cal prostatectomy (RP) or local radiotherapy (RT) has a role in 
certain at-risk patients, although it is not recommended in 
low-risk PCa owing to the significant side-effects associated 
with RT and androgen deprivation therapy (ADT). The rec-
ommendations for salvage therapy differ depending on 
whether BCR occurs after RP or primary RT, and in either case, 
definitive evidence regarding the best strategy is lacking. 
Options for treatment of BCR after RP are RT at least to the 
prostatic bed, complete or intermittent ADT, or observation; 
for BCR after RT, salvage RP, cryotherapy, complete or inter-
mittent ADT, brachytherapy, high-intensity focused ultra-
sound (HIFU), or observation can be considered. Many pa-
tient- and cancer-specific factors need to be taken into ac-
count when deciding on the best strategy, and optimal 
management depends on the involvement of a multidisci-
plinary team, consultation with the patient themselves, and 
the adoption of an individualised approach. Improvements 
in imaging techniques may enable earlier detection of me-
tastases, which will hopefully refine future management de-
cisions. © 2017 S. Karger AG, Basel
Introduction
In prostate cancer (PCa) that has not extended beyond 
the prostate gland, the risk of progression can vary sig-
nificantly, and thus management approaches range from 
active surveillance [1–3] to treatment with curative in-
tent, which includes radical prostatectomy (RP) or pri-
mary definitive radiotherapy (RT) [1, 4]. Besides RP and 
RT (external-beam radiation therapy or brachytherapy), 
other modalities that have emerged as therapeutic op-
tions for the treatment of localised PCa include high-in-
tensity focused ultrasound (HIFU) and cryosurgery. A 
relatively newer development is focal ablative therapy, 
whereby ablation is undertaken on smaller tumours in a 
Walter Artibani    
Antonio Benito Porcaro    
Vincenzo De Marco    
Maria A. Cerruto    
Salvatore Siracusano    
Department of Urology, University of 
Verona, Verona, Italy
Management of Biochemical 
Recurrence after Primary Curative 
Treatment for Prostate Cancer:  
A Review
Artibani/Porcaro/De Marco/Cerruto/
Siracusano
Urol Int2
DOI: 10.1159/000481438
R
ev
ie
w
precise, organ-sparing manner, thereby limiting toxicity 
[1].
The goal of RP is to eradicate the disease while preserv-
ing continence and if possible sexual potency [1, 5]; loss 
of either or both of these has a significant impact on pa-
tients’ quality of life (QoL). In low-risk PCa, active sur-
veillance is often the recommended approach [1, 6]. 
There is stronger evidence of the benefits of RP for inter-
mediate-risk localised PCa than there is for low-risk dis-
ease [1, 7, 8]. However, the decision to offer RP to patients 
with intermediate-risk PCa should be based upon indi-
vidualised assessment, taking into account the patient’s 
life expectancy and comorbidity, for example. In high-
risk PCa, RP may be a reasonable first step in selected pa-
tients with a low tumour volume, provided the tumour is 
not fixed to the pelvic wall or there is no invasion of the 
urethral sphincter [1]. Several retrospective case series 
with high-risk PCa have demonstrated good outcomes 
after RP in the context of a multimodal approach (includ-
ing adjuvant or salvage androgen deprivation therapy 
[ADT] and/or RT) [9–12].
RT with dose escalation (range 74–80 Gy) has a posi-
tive impact upon biochemical progression in localised 
PCa, but data is not available for the relative benefits in 
different risk groups [1]. Results from ProtecT – a large-
scale clinical trial, in which 1,643 men with PCa have been 
randomly assigned to either active surveillance, RP or 
RT – may soon provide conclusive data on the value of 
definitive RT for localised PCa [13].
Local therapy for PCa – RP or definitive RT – is cura-
tive in many patients, and remarkable technological ad-
vances over the last decade have led to efficacy improve-
ments in both RP and RT. Despite this, biochemical re-
currence (BCR) – that is, prostate-specific antigen (PSA) 
increase – still occurs in 27–53% of patients after defini-
tive local therapy [1]. Within 10 years, 20–40% of post-RP 
[14, 15] and 30–50% of post-RT [16] patients will experi-
ence BCR. Once BCR occurs, the patient is understood to 
have recurrent PCa, even if there are no signs or symp-
toms of locally recurrent or metastatic disease. Despite 
signifying the return of disease, BCR alone may have no 
impact on either the patient’s QoL or their overall sur-
vival (OS). The challenge faced by clinicians in managing 
BCR is to prevent or delay the onset of metastatic disease 
and the resulting morbidity and mortality, while taking 
into account the negative impact that treatment may have 
on patients’ QoL, and at the same time avoiding over-
treating PCa that is at low risk of clinical progression. 
Physicians are faced with a number of options for manag-
ing patients who experience BCR (Fig. 1), and often the 
best way forward is unclear. This review therefore dis-
cusses the optimal approach to the management of BCR 
after RP or definitive RT. Adjuvant approaches to reduce 
the risk of post-RP/RT recurrence are also discussed. 
RP or primary RT with
curative intent
Biochemical
recurrence
Deferred treatment
Until signs of local
recurrence and/or
metastatic progression?
Immediate treatment
Radiation? ADT? Combined?
Continuous? Intermittent?Immediate? Earlysalvage?
Fig. 1. Decisions faced by physicians upon 
BCR after primary curative treatment. 
ADT, androgen deprivation therapy; BCR, 
biochemical recurrence; RP, radical pros-
tatectomy; RT, radiotherapy.
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Search Strategy
Relevant papers to inform this review were identified 
through PubMed searches in July 2017 using the terms 
“prostate cancer” AND “radical prostatectomy” AND 
“recurrence” AND “management”; and “prostate cancer” 
AND “radiation therapy” AND “recurrence” AND “man-
agement.” Search results were restricted to clinical trials 
with a start date on or after January 1, 2015. Treatment 
recommendations provided in this review reflect the lat-
est relevant guidance from the European Association of 
Urology (EAU; 2016) [1], the National Comprehensive 
Cancer Network (2016) [17], and the European Society 
for Medical Oncology (2015) [18]. These guidelines were 
reviewed for original data sources to supplement the 
aforementioned literature searches. The guidelines were 
broadly in accordance with each other. 
Defining BCR
The definition of BCR differs depending on whether 
men have undergone RP or have received primary cura-
tive RT. After RP, PSA typically falls to an undetectable 
level, and BCR is defined as 2 consecutive PSA values 
higher than 0.2 ng/mL and rising [19]. After RT, PSA lev-
els do not typically fall to zero, and BCR is defined as any 
PSA increase greater than or equal to 2 ng/mL higher than 
the PSA nadir [20]. The risk of PCa-specific mortality dif-
fers depending on whether the PSA recurrence was after 
RP or primary RT, and it is therefore important to inter-
pret BCR endpoints in the context of the initial treatment 
[1].
The Natural History of BCR
Although a rising PSA level universally precedes me-
tastasis and PCa-specific mortality [1], BCR is not a sur-
rogate for PCa-specific mortality or OS, and may pre-date 
local recurrence or metastasis by several years. On aver-
age, BCR precedes the appearance of clinical metastasis 
by 8 years after RP [21] and by 7 years after primary de-
finitive RT [22].
The natural history of BCR and the risk of subsequent 
metastasis may be predicted by pre- and post-treatment 
clinical features (Table 1). These prognostic indicators are 
used as a means to assess the patient’s level of risk, and 
therefore, help physicians to determine whether to initiate 
early treatment or to adopt a strategy of active surveillance. 
Treatment decisions following BCR must balance the risk 
of metastatic disease or death with the impact of treatment, 
and necessitate involvement of a multi-disciplinary team, 
as well as informing the patient of the potential for a pro-
longed natural history of PSA-only recurrence [1]. 
BCR after RP
As mentioned, not all patients with BCR after RP 
will develop clinical failure; indeed, published reports 
suggest that an estimated 24–34% of men who develop 
Table 1. Pre- and post-treatment prognostic factors in PSA-recurrent prostate cancer [21, 28, 33, 99]
Pre-treatment (factors 
relating to initial tumour)
Post-treatment
Biochemical features Baseline PSA
Tumour stage (T-stage)* PSA kinetics– PSA-DT
– PSA velocity
Time to biochemical recurrence**
Absolute PSA value at time of testing
Pathologic features Gleason score Gleason score
Surgical margin status
Extracapsular extension
Seminal vesicle involvement
Lymph node status score* Based on both biochemical and biopsy findings.** Studies report conflicting results as to whether time to biochemical recurrence is a prognostic indicator.
PSA, prostate-specific antigen; PSA-DT, PSA doubling time.
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Furthermore, it has been estimated that 2–6% of men 
who experience BCR after RP may die from PCa [21, 
23].
Several clinical characteristics can help determine 
those patients most at risk of metastasis and PCa-specific 
mortality post-RP, and thus help guide treatment deci-
sions. For example, BCR in post-RP men with positive 
surgical margins is more likely to be a result of local recur-
rence [24]. If BCR occurs within 6 months of RP, this is a 
strong indication that metastasis has occurred [25], and a 
short PSA doubling time (PSA-DT), regardless of the 
time to BCR, is correlated with early clinical recurrence 
[26]. The interval to BCR following RP does not affect 
PCa-specific mortality in men with low-risk PCa; how-
ever, in men with high-risk disease, early BCR substan-
tially increases mortality [27].
By amalgamating the available evidence, men who 
may be at high risk of metastases and PCa-specific mor-
tality have been identified as those with a PSA-DT of 
<3  months, seminal vesicle invasion (pT3b), specimen 
Gleason score 8–10, or BCR within 3 years of RP [1, 14, 
28–30]. An area of uncertainty regarding whether to clas-
sify a patient into this high-risk subgroup or as at low risk 
exists for when their PSA-DT is between 3 and 12 months 
[1].
BCR after RT
After definitive RT, factors that signal a high risk of 
metastases and PCa-specific mortality are similar to those 
after RP: a PSA-DT of <3 months, clinical stage cT3b–T4, 
biopsy Gleason score 8–10, or BCR within 3 years of RT 
[1, 30–32]. An analogous area of uncertainty for risk 
stratification also exists for recurrence after RT; in this 
case, when the patient’s PSA-DT is between 3 and 15 
months [1].
Assessing Metastases and Local Recurrence
Once BCR has been detected, it is important to try to 
establish whether this represents local recurrence or dis-
seminated (i.e., metastatic) disease, or both, in order to 
guide subsequent treatment decisions. Importantly, met-
astatic disease must be acceptably ruled out before sub-
jecting patients to local salvage treatment, owing to the 
significant morbidity associated with such treatments. 
Regardless of whether BCR is detected post-RP or post-
RT, the same principles of imaging apply. 
Detecting Metastases
In case of BCR, the current standard workup for de-
tecting metastases involves a bone scan and abdomino-
pelvic CT. These imaging techniques rarely detect metas-
tases in asymptomatic patients; hence, the need for 
 physicians to rely on the aforementioned pre- and post-
treatment metastatic risk factors to predict the likelihood 
of clinical progression. For example, the probability of a 
positive bone scan in men with PSA-only relapse after RP 
is <5% if the PSA level is <7 ng/mL [33, 34]. Likewise, CT 
scanning has low sensitivity for detecting local recurrence 
or lymph node metastases after RP [33]; in men experi-
encing BCR postoperatively, this imaging technique 
yields a positive result in only 11–14% of cases [35, 36].
Earlier detection of metastases may help drive man-
agement decisions, and more sensitive methods are there-
fore needed. Several imaging techniques and agents are 
being used to try to detect metastases earlier than is cur-
rently possible, including, for example, NaF scintigraphy, 
PET scans using agents such as choline, acetate or pros-
tate-specific membrane antigen (PSMA), whole body dif-
fusion-weighted MRI, spinal MRI, and lymph node MRI 
[37, 38].
11C-choline PET/CT may offer better sensitivity and 
specificity for detecting bone metastases [39–41]. 11C-
choline PET/CT has been shown to detect bone metasta-
ses in up to 15% of patients who have BCR after RP but 
negative bone scans [42]. Unfortunately, the high cost of 
choline PET/CT prevents its recommendation for use in 
all cases of BCR, and one suggestion is to limit use of this 
technique to patients fit enough for curative salvage treat-
ment [1]. Alternatively, it may be possible to target the use 
of this technique to certain individuals after RP (e.g., if the 
patient’s PSA level is >1 or >2 ng/mL); however, the pre-
cise cut-off level and the impact of PSA velocity require 
definition. PSA cut-off levels to target the use of 11C-cho-
line PET/CT following BCR after RT are even harder to 
define than they are for post-RP BCR [1].
Whole-body diffusion-weighted MRI may also im-
prove detection of bone metastases in patients with high-
risk PCa [43–46] but little is known about this technique 
in the context of BCR after RP or RT. The 68Ga-PSMA-
ligand is highly specific for PCa, and the use of this radio-
tracer with PET/CT imaging is emerging as a promising 
new technique for the detection of lymph node and bone 
metastases. In a retrospective analysis of 319 patients who 
underwent this imaging procedure, one or more lesions 
indicative of PCa were detected in 82.8% of patients. High 
values were recorded for sensitivity (76.6%), specificity 
(100%), negative predictive value (91.4%) and positive 
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predictive value (100%) [38]. Despite emerging as a supe-
rior imaging system to those currently in use, PSMA PET/
CT is currently only being implemented in a few centres. 
Detecting Local Recurrence
The current options for optimising detection of local 
recurrence after RP or RT are outlined in Table 2. 
Adjuvant Therapy for Radical Prostatectomy
Before addressing the management options for post-
RP BCR, it is necessary to examine the question of wheth-
er it is possible to reduce post-RP recurrence by targeting 
men most at risk with adjuvant therapy. 
Adjuvant RT for RP
While there is no justification for adjuvant RT (aRT) 
in all men, evidence suggests that men with positive mar-
gins and pT3 disease have a greater than 50% risk of fail-
ure 10 years after RP [15, 47, 48] and are therefore con-
sidered suitable candidates for aRT. In a Cochrane review 
of 3 randomised controlled trials (RCTs) involving 1,815 
patients with high-risk features found at the time of sur-
gery (e.g., seminal vesicle invasion), aRT improved bio-
chemical progression-free survival (PFS) compared with 
RP alone at 5 and 10 years (risk difference at 5 years: 
–0.16; 95% confidence intervals [CI] –0.21 to –0.11 and 
at 10 years: –0.29; 95% CI –0.39 to –0.19) [49].
Other studies also suggest that the use of aRT may sig-
nificantly reduce BCR (hazard ratio [HR] 0.48) in the pres-
ence of adverse pathology after RP, despite the use of RT 
doses that are lower than typically used today in routine 
practice [50–53]. However, the data from these studies 
may be questioned due to some important contamination 
biases; for example, 30–34% of patients had detectable 
PSA at inclusion and therefore received salvage RT (sRT) 
rather than aRT. There are questions, therefore, surround-
ing the quality of the efficacy data, as well as the high num-
bers needed to treat for preventing cancer-specific death 
(55.6–66.7 men to prevent one PCa-specific death) [50, 
51]. It is also important to consider the potential toxicity 
and negative impact upon QoL of aRT (including persis-
tent and late occurring adverse events [AEs]) [53]. 
While aRT may be an option for men who undergo RP, 
the oncological benefits must be balanced against the 
negative impact on QoL, and the decision on whether to 
initiate any treatment must be a shared decision with the 
patient, after an informed discussion with them. 
Neoadjuvant or Adjuvant Androgen Deprivation 
Therapy for RP
Neoadjuvant or adjuvant ADT with RP may have ben-
efits in some patients with local or locally advanced PCa, 
where there is evidence that this approach provides a sig-
nificant survival advantage [54, 55]. The European Asso-
ciation of Urology (EAU) guidelines recommend that ad-
juvant ADT be offered upon detection of nodal involve-
ment during RP [1]. 
Management of Post-Radical Prostatectomy 
Recurrence
The options for treatment of recurrence after RP are, 
according to the EAU, RT at least to the prostatic bed, 
complete or intermittent ADT, or observation [1].
Salvage RT
The importance of establishing whether BCR repre-
sents local recurrence or metastatic disease lies in the abil-
ity or not to salvage the surgical failure with RT. Treat-
Table 2. Current options for improving assessment of local recurrence of prostate cancer after radical prostatectomy or definitive radio-
therapy [1, 37]
After radical prostatectomy After definitive radiotherapy
TRUS is not effective Ultrasonography not reliable enough
Biopsy is unnecessary Biopsy is a major predictor of outcome
Choline PET is promising – When performed 18–24 months after treatment
–But sensitivity is not optimum when PSA <0.5 ng/mL mp-MRI can be useful in directing core sampling
The threshold often used for salvage radiotherapy
mp-MRI, multiparametric-magnetic resonance imaging; PET, positron emission tomography; PSA, prostate-specific antigen; TRUS, 
transrectal ultrasound.
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w ment with sRT is most likely to be effective when the ris-ing PSA level is still low, when the PCa is less likely to have 
metastasised (i.e., when the disease is more likely to be 
confined to the prostate bed). 
Early sRT delivered to patients with a short PSA-DT, 
or while the PSA level remains under 2 ng/mL, has been 
shown to improve survival in patients with BCR after RP. 
In a retrospective study of men with BCR after RP, at a 
median follow-up of 6 years after BCR, sRT (alone or with 
ADT) was associated with a threefold improvement in 
PCa-specific survival compared with observation, al-
though only in men with a PSA-DT of <6 months (HR 
0.32; 95% CI 0.19–0.54; p  < 0.001) [56]. sRT initiated 
while the PSA level was 2 ng/mL or lower was associated 
with a significant increase in PCa-specific survival (HR 
0.27; 95% CI 0.15–0.50). However, even in patients with 
a PSA level greater than 2 ng/mL, there was a significant 
PCa-specific survival advantage to sRT, so long as they 
had a PSA-DT of under 6 months (PSA level ≤2 ng/mL: 
HR 0.10; 95% CI 0.03–0.32; PSA level >2 ng/mL: HR 0.34; 
95% CI 0.12–0.95). However, if initiated more than 
2 years after BCR, sRT provided no significant increase in 
PCa-specific survival, regardless of the PSA-DT. In an-
other retrospective study, at a median follow-up of 11.3 
years, early (within 1 year of BCR) sRT led to a significant 
reduction in all-cause mortality both in men with a PSA-
DT of <6 months (HR 0.53; 95% CI 0.31–0.90; p = 0.02) 
and in men with a PSA-DT of 6 months or longer (HR 
0.52; 95% CI 0.34–0.80; p = 0.003) [57].
Currently, there is no definitive recommendation on 
the relative merits of aRT versus early sRT. One study 
suggested that early sRT was similar to aRT in improving 
BCR-free survival in most patients with pT3pN0, R0–R1 
PCa previously treated with RP. This study therefore sug-
gests that early sRT, when given at a low PSA level (≤0.5 
ng/mL), can significantly reduce overtreatment associ-
ated with aRT [58]. Another study reported no significant 
difference in OS between aRT given within 9 months of 
RP and delayed sRT (≥12 months post-RP) [59]. While 
genito-urinary toxicity was similar with early aRT and 
sRT, the former may be associated with lower rates of gas-
trointestinal (GI) events, with HRs of 0.80 and 0.70 for 
procedure-defined and diagnosis-defined GI events, re-
spectively [59]. This may be an important consideration 
for patients with comorbidity, and challenges the belief 
that delaying RT reduces the risk of radiation-related 
complications. 
Following RP with BCR, adding ADT to sRT may pro-
vide benefits over sRT alone. For example, the addition of 
ADT to sRT has shown benefit in terms of biochemical 
PFS after 5 years in retrospective series [60, 61] and in PFS 
for high-risk tumours [62]. In the recently published dou-
ble-blind, placebo-controlled RTOG trial of 760 patients 
who underwent sRT with or without 2 years of daily bi-
calutamide, the 12-year actuarial OS rate was 76.3% in the 
bicalutamide group and 71.3% in the group receiving dai-
ly placebo tablets (HR 0.77; 95% CI 0.59–0.99; p = 0.04). 
The corresponding 12-year incidence of death from PCa 
was 5.8 and 13.4%, respectively (p < 0.001), and the cu-
mulative incidence of metastatic PCa was 14.5 and 23.0%, 
respectively (p = 0.005) [63]. Another RCT – GETUG-
AFU 16 – compared standard sRT with or without 
6 months of goserelin ADT in patients with a PSA-DT of 
over 6 months at relapse. Addition of ADT significantly 
improved biochemical and clinical progression after 
5 years compared with sRT alone (80% [95% CI 75–84] 
vs. 62% [95% CI 57–67] respectively; HR 0.50 [95% CI 
0.38–0.66]; p < 0.0001), while OS remained high in both 
study arms [64]. 
Two ongoing trials may help to guide practice in fu-
ture: RADICALS aims to recruit approximately 3,000 
men with PCa and will study the best way to use RT after 
RP, as well as the potential merits of additional ADT in 
this context; and RAVES will compare early sRT with aRT 
in men with pT3 disease and/or positive margins after RP 
[65].
Salvage Androgen Deprivation Therapy
Recurrence following RP can potentially be managed 
with salvage ADT, although data supporting this use is 
generally obtained from retrospective studies [1]. Not all 
patients with BCR after primary curative treatment ben-
efit from salvage ADT; however, a favourable effect is ob-
served in a high-risk group, which may be defined as hav-
ing a short PSA-DT and/or by tumour characteristics [66, 
67]. Factors that may favour ADT after RP include a very 
high risk of clinical recurrence, good recovery of conti-
nence, long life expectancy, and the patient being anxious 
about the future or not being ready to accept the idea of 
sRT.
The National Cancer Institute of Canada PR-7 trial 
compared intermittent with continuous ADT in men 
with BCR and no evidence of metastatic disease after de-
finitive or salvage RT and RP. OS in the intermittent arm 
was not inferior to that in the continuous arm, and inter-
mittent therapy was associated with beneficial effects on 
certain domains of QoL. Salvage ADT for BCR may there-
fore be most appropriately delivered in an intermittent 
fashion, with the possible exception of patients with a 
Gleason score of 8 or higher [68].
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of over 2,000 patients experiencing BCR who had either 
undergone RP (69%) or RT (31%) – compared immediate 
ADT (patients started on ADT within 3 months of PSA 
relapse) with deferred ADT (patients started ADT ≥2 years 
after PSA relapse or when they presented with metastasis, 
symptoms or a short PSA-DT) [69]. Interestingly, this 
study found no differences in either 5- or 10-year OS be-
tween the 2 strategies. In this study, the HR for mortality 
for immediate versus deferred ADT was 0.91 (95% CI 
0.52–1.60), which corresponded to an estimated 5-year 
survival of 85.7% (95% CI 77.7–93.7%) and 87.7% (95% CI 
84.8–90.6%), respectively. The 10-year estimated survival 
in this study was 69.8% (95% CI 54.5–85.1%) and 69.3% 
(95% CI 60.7–77.9%), respectively [69]. These findings 
suggest there is no difference in OS regardless of whether 
ADT is started immediately upon PSA relapse or is de-
ferred until disease progression. Another study compared 
ultra-early salvage ADT (patients who began salvage ADT 
before reaching the standardised definition of BCR) with 
early salvage ADT (patients who started salvage ADT 
when they met the definition). Fewer patients receiving 
ultra-early salvage ADT experienced BCR compared with 
those receiving standard early salvage ADT (one patient 
[2%] vs. 12 patients [17.1%], respectively). This indicates 
that salvage ADT could potentially be most effective when 
administered before patients meet the definition of BCR.
Observation
Observation until the development of clinically evi-
dent metastatic disease may be suitable for patients with 
low-risk features (e.g., PSA-DT >12 months, time to BCR 
>3 years, Gleason score <7 and stage ≤T3a) or patients 
who are unsuitable for, or unwilling to receive, salvage 
therapy [1]. The median time to the development of me-
tastasis from the time of post-RP PSA level elevation is 
8 years; upon development of metastatic disease, the me-
dian actuarial time to death is 5 years [21]. For patients 
with BCR following RP and with a PSA-DT of longer than 
1 year, a “wait and see” strategy is considered a viable op-
tion, rather than proceeding directly to sRT [23].
Summary
Contemporary data concerning improved stratifica-
tion of high-risk patients, greater knowledge about the 
impact of aRT on urinary continence, more accurate re-
staging, more effective RP and RT techniques, and the 
potential role of early sRT and salvage ADT needs to be 
taken into account in order to reach a personalised, shared 
decision, balancing quantity of life with QoL. Crucially, 
the patient must have a strong understanding of the ad-
vantages and disadvantages of any treatment before any 
decision is made. 
Neoadjuvant and Adjuvant Hormonal Therapy 
with RT
A consideration of the role of (neo) adjuvant therapy 
with RT is useful before examining the treatment choices 
in the setting of BCR after RT. The combination of RT 
with gonadotrophin-releasing hormone ADT is proven 
to be superior to RT alone followed by deferred ADT 
upon BCR [1]. Use of adjuvant or neoadjuvant ADT with 
RT in patients with locally advanced PCa is now standard 
practice. 
A meta-analysis showed that for localised and locally 
advanced PCa, neoadjuvant ADT before RT significantly 
improved biochemical disease-free survival and clinical 
disease-free survival [54]. For patients with a Gleason 
score of 2–6, neoadjuvant ADT before RT significantly 
improved OS, and a short duration of neoadjuvant ADT 
should therefore be considered in such patients [54].
While the evidence strongly favours neoadjuvant/ad-
juvant therapy in patients with locally advanced PCa [1, 
70], the value of this approach in intermediate- or high-
risk localised PCa is less clear [1, 71, 72]. Rates of BCR 
may be reduced with adjuvant or neoadjuvant ADT in 
carefully selected patients with intermediate- or high-risk 
localised PCa [1, 73], and the decision to use adjuvant or 
neoadjuvant ADT with RT in such patients should there-
fore be based upon individualised assessment.
Management of Post-RT Recurrence
In the case of PSA-only recurrence after RT, the timing 
and mode of treatment remain controversial due to the 
low quality of the available evidence. Treatment options 
according to the EAU are salvage RP, cryotherapy, con-
tinuous or intermittent ADT, brachytherapy, HIFU, or 
observation [1].
RP
Of the available salvage therapies, RP provides the 
greatest likelihood of local control, but is associated with 
worse functional outcomes and an increased risk of AEs 
(e.g., urinary retention, urinary fistula, and fistula) com-
pared with primary RP. Salvage RP should therefore be 
Artibani/Porcaro/De Marco/Cerruto/
Siracusano
Urol Int8
DOI: 10.1159/000481438
R
ev
ie
w considered only for patients with low comorbidity, and should be performed by an experienced surgeon. Across 
several case series of salvage RP following BCR post-RT, 
the BCR-free probability ranged from 37 to 87% [74–77], 
with one study reporting a PCa-specific survival rate of 
83% [74]. The pre-salvage RP PSA level and prostate bi-
opsy Gleason score were the strongest predictors of PFS 
and PCa-specific survival [78]. Factors that may indicate 
salvage RP include: a life expectancy of 10 years or longer, 
PSA level under 10 ng/mL, Gleason score of 7 or lower, 
no lymph node involvement, and initial clinical staging of 
T1 or T2 [78].
Cryotherapy
Salvage cryotherapy may be an alternative to salvage 
RP; however, despite improvements in complication 
rates [79–83], studies have shown disappointing results 
in terms of 5-year biochemical disease-free survival after 
cryotherapy [80, 82, 84]. For example, no significant dif-
ference in PCa-specific survival at 5 years was found be-
tween salvage cryotherapy and salvage RP (96 vs. 98%, 
respectively; p  = 0.283) [84]. The authors of this study 
concluded that young, healthy patients with BCR after RT 
should consider salvage RP as it offers superior biochem-
ical disease-free survival compared with cryotherapy and 
may offer a better chance of cure.
Androgen Deprivation Therapy
It is as yet unclear under what circumstances ADT 
should be used in a salvage setting. Salvage ADT (typically 
for ≥2 years for patients with high-risk disease) for post-
RT BCR has been associated with significantly better me-
tastases-free survival and disease-specific survival at 
7 years’ follow-up versus observation but only for patients 
with a PSA-DT of <6 months [67]. At 7 years, freedom 
from distant metastasis for patients with a PSA-DT of 
<6 months was 50%, compared with 83% if the PSA-DT 
was over 6 months (p = 0.0001); PCa-specific survival was 
61 and 85% respectively (p = 0.0001), and OS was 47 and 
53%, respectively (p = 0.04). PSA-DT may, therefore, be an 
important factor in determining the efficacy of ADT post-
RT. Indeed, in patients with BCR following local therapy, 
changes in PSA-DT after treatment initiation have been 
shown to be prognostic for metastasis-free survival [85].
In a large non-inferiority RCT in patients with a PSA 
level greater than 3 ng/mL 1 year post-RT, intermittent 
ADT was shown to be non-inferior to continuous ADT 
in terms of OS (median: 8.8 vs. 9.1 years, respectively; HR 
for death, 1.02; 95% CI 0.86–1.21) [86]. An intermittent 
approach to therapy may have a beneficial effect on phys-
ical function, fatigue, urinary problems, hot flashes and 
sexual function [86], and may be more attractive than 
continuous ADT in cases where patients respond initial-
ly. However, evidence from the use of ADT – albeit in a 
non-salvage setting – appears to refute the purported 
benefits of intermittent over continuous therapy. In a re-
cent trial, intermittent ADT was found to be inferior to 
continuous ADT on survival outcomes [87]. Further-
more, in a secondary analysis of the trial, ischaemic and 
thrombotic events were more frequent with intermittent 
ADT compared with continuous ADT (10-year cumula-
tive incidence: 33 vs. 24%, respectively; p = 0.02) [88].
As discussed earlier, limited data is available regarding 
the optimal timing of salvage ADT. 
Brachytherapy
The chance of cure using salvage brachytherapy fol-
lowing local recurrence post RT is low, as the total dose is 
limited [1]. For carefully selected patients, high- or low-
dose rate brachytherapy may be an effective treatment 
option with an acceptable toxicity profile [89–91]. In one 
study, for example, at 5 years after salvage, OS was an es-
timated 92% (95% CI 80–97%) and biochemical control 
was 51% (95% CI 34–66%). The rate of complications in 
this study was also low, with just 2% acute and 2% late 
grade 3 genitourinary toxicities, no grade 2 or higher 
acute GI events and 4% grade 2 GI late events. However, 
due to lack of robust evidence and the risk of severe AEs 
with brachytherapy, only experienced centres should of-
fer this treatment [1].
High-Intensity Focused Ultrasound
HIFU is a more recent option for post-radiation recur-
rent PCa; available data are therefore from shorter-term 
studies (mostly from a single treatment centre) and are 
limited [92–96].
Observation
For patients experiencing BCR post-RP, observation is 
appropriate for those with signs of only local recurrence 
(e.g., late BCR and a slow PSA rise) who do not wish to 
undergo second-line curative options [1].
Other Recommendations
Beyond observation, it is prudent to recommend that 
patients take regular exercise and adopt a healthy diet. 
Certainly, physical activity has been linked to a lower 
risk of PCa-specific death [97], and increasing evidence 
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appropriate to assess cardiovascular risk in these pa-
tients, and prescribe prophylactic medication where 
necessary.
Conclusions
How best to treat a rising PSA following treatment of 
localised PCa with curative intent remains an important 
clinical question. After RP or primary curative RT, the 
risk of recurrence and the risk that recurrence will subse-
quently lead to metastasis need to be assessed in order to 
optimise management decisions. Current evidence pro-
vides clinicians with only general guidance, and it is vital 
that disease management strategies be individualised, 
that there is involvement of a multi-disciplinary team, 
and that every patient be involved in the decision-making 
process. Management decisions therefore often come 
down to patient and provider preferences, taking into ac-
count the probability of disease progression and the risks 
and benefits of treatment. Improved methods for the ear-
ly detection of early PCa progression and early metastasis 
will enable treatment to become more refined in the fu-
ture.
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